A randomized open-label phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Melanoma
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. . Histologically confirmed unresectable or metastatic stage IIIB/C/D or IV melanoma. 2. Previously treated for unresectable or metastatic melanoma.

You may not be eligible for this study if the following are true:

  • 1. Patients with uveal or mucosal melanoma. 2. Presence of clinically active or unstable brain metastasis. 3. Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.